Skip to main content

A composite photo made available by the Oregon Health and Science University shows a sequence of the development of embryos after co-injection of a gene-correcting enzyme and sperm from a donor with a genetic mutation known to cause hypertrophic cardiomyopathy.OREGON HEALTH & SCIENCE UNIVERSI

It appears, by all accounts, to be a momentous scientific achievement – and possibly a turning point in human evolution. In a study released last week, scientists at Oregon Health and Science University confirmed they were able to modify genes in viable human embryos, proving the potential to permanently alter the makeup of a genetic line.

In this case, that meant replacing and repairing a mutated gene that causes a common and deadly heart disorder. But the possibilities heralded by gene-editing technology are endless, the scenarios as divided as they are bold. In some visions, it leads to a population of designer babies or "consumer eugenics." Others imagine a utopia of scientific advancement where humans live free of disease, and devastating conditions are eradicated for the betterment of humanity. What direction the technology will take is the topic of much debate.

"The big thing which is making the scientific and ethics community get excited, and on the other hand a little bit hot and bothered, is it's a mechanism to change genes for multiple generations," says Dr. Alice Virani, a genetic counsellor and director of ethics at British Columbia's Provincial Health Services Authority. "There are two ways to look at it, the more realistic ramifications and the sci-fi, if-this-was-out-of-control ramifications."

Opinion: Gene editing is not about 'designer babies'

The team at the Oregon university's Center for Embryonic Cell and Gene Therapy used technology called CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, to repair or edit the gene carrying the heart disorder, seemingly with greater success than previous attempts by scientists in China.

News of the research has been anxiously anticipated by many in the field, both for what it means for the potential eradication of a disease such as hypertrophic cardiomyopathy and for the fundamental questions it raises about human reproduction, health and society.

When the study was leaked days before its publication in the journal Nature, its lead scientist, Dr. Shoukhrat Mitalipov, attributed the release to "likely a combination of hot words: CRISPR, gene-editing, and designer babies."

The study – and its combination of hot words – didn't disappoint.

The New York Times hailed the "milestone in research," while The New York Post cried BABE NEW WORLD and described "an amazing – and slightly terrifying – breakthrough." A headline on Vox declared simply, This Is Huge.

Even actor Ashton Kutcher tweeted enthusiastically about the scientific breakthrough, writing: "Scientists successfully used CRISPR to fix a mutation that causes disease. This is why I wanted to be a geneticist!"

The tweet ignited among his followers the same range of responses that are always so keenly tied to the issue of changing human genes, from hope that devastating conditions such as muscular dystrophy will be eradicated, to fear about the unknown consequences of "playing God."

Dr. Timothy Caulfield, a Canada Research Chair in Health Law and Policy and professor at the University of Alberta, says the polarized and dramatic response he has seen in recent days reminds him of early reaction to stem-cell science, where, he says, "It was either going to be cloned armies, or we were going to eradicate all disease."

In fact, neither has turned out to be the case, and so it may be with gene editing as well.

"We need to be cautious not to hype the benefits and be cautious not to hype the ethical concerns," he says. "There are real issues on both sides of the debate but let's make sure our discourse is evidence-formed."

He described the new research as "a genuinely exciting area," and said the potential of CRISPR – which is used not only in human genetics, but also has potentially revolutionary applications for agriculture, animals, plants and food – "has introduced both exciting possibilities and reasons for deep policy reflection."

Erika Kleiderman, a lawyer and academic whose work focuses on gene-editing technologies, stem-cell research and regenerative medicine at the Centre of Genomics and Policy at McGill University, says the Oregon team's research is exciting because it confirms the ability of CRISPR technology to repair genetic mutations, and establishes the basic safety of the technique in a research context. And while she said people often go straight to thinking about the potential for manipulating genes to create so-called designer babies, "a concept that is cool but also quite frightening," the medical implications could be equally staggering, and are far more likely.

"For example, something like Huntington disease," she says. "Being able to prevent that or treat that one day, in my opinion, would be a fantastic leap for our scientific knowledge and medical advancement. That being said, people will raise the eugenics argument. Is that a possibility? Yes. Are we close to that? I don't think so."

Canada has strict laws around genetic modification and editing, and altering genes in a way that could be passed on to future generations is a criminal offence under the Assisted Human Reproduction Act, punishable with fines up to $500,000 or 10 years in prison.

But as the technology takes a large step forward, Ms. Kleiderman and Dr. Caulfield and are among a group of Canadian scientists and academics calling for less regulation around genetic science and research in Canada, not more.

Both were involved in the creation of an editorial published in the journal Regenerative Medicine in January calling for new consideration of the issues and ethics involved in gene editing, and a revision of Canadian legal policy.

"A criminal ban is a suboptimal policy tool for science as it is inflexible, stifles public debate, and hinders responsiveness to the evolving nature of science and societal attitudes," the editorial read. It was signed by seven other experts and ethicists, and came out of a think tank on the future of human gene editing in Canada held at McGill last summer.

Dr. Caulfield says legal prohibition of certain genetic research doesn't make sense when we don't yet know or understand where the science is going, or what the benefits or harms could be. Instead, he says he believes in regulation in problematic areas, while allowing for studies and trials. He says that some of the "slippery slope" scenarios people fear – such as using genetic modification for human enhancement and to achieve superficial traits such as height – remain distant possibilities given the complexity of the science.

That is not to say there are not risks or issues to be addressed as the technology continues to evolve. Ms. Kleiderman says that includes consideration of the potential risk to future generations, the safety of the technology and other irrevocable, if unintended, consequences, although she says those risks are not unique to gene modification but true of all technologies.

"When it comes to CRISPR, one of the areas it would be most beneficial is with the treatment of prevention of disease which I think most people would be in agreement with," she says. "Of course, we need to be mindful of doing not-so-positive things with it, like going down the enhancement route."

She said other potential issues, such as the preservation of human diversity and individuality, the welfare of children born from this technology and the potential for creating new forms of inequality, discrimination or societal conflict, all require significant consideration and research.

There is time. Although the technology is moving quickly, there is still a long way before gene editing is used in clinical human trials. Even after that, Dr. Virani says for the foreseeable future the technology will most likely be used by a small group of people in specific scenarios related to the prevention of serious genetic disease.

"I'm not saying we shouldn't be concerned about those potential issues, but sometimes we make that leap too quickly," she said. "We don't necessarily [think] that the most likely scenario is that couples will use this technology on a very limited basis if they know their child may potentially have a devastating genetic condition. That's not something that suddenly everyone is going to start to do. I think there's sometimes that leap to, 'Oh, we can create designer babies,' but I think we're very much in the lessening-burden-of-disease phase rather than the designer-baby phase, though that's where people's minds go."

Dr. Virani said one of her own concerns is the possibility of "off-target effects," where changing a gene unexpectedly alters something else in the genome. Other concerns are more social reality than science fiction, including that the technology and the ability to prevent disease may only be available to those who can pay for it. Eradicating a horrible disease is one thing. Eradicating it only for families who can afford it is another.

"So is it going to look like just the wealthy are going to be able to afford this type of technology?" she asks. "That's very problematic in my eyes from an ethics point of view, and thinking about fairness in society. If only poor people get Huntington disease, then the lobby to support Huntington disease research is greatly diminished. It's kind of like a two-fold negative effect."

On Thursday, the American Journal of Human Genetics ran a policy statement signed by 11 organizations from around the world, including the Canadian Association of Genetic Counsellors, urging a "cautious but pro-active approach" as the science moves forward. The statement includes an agreement that gene editing should not yet be performed in embryos carried on to human pregnancy. (The embryos used in the Oregon research were created only for the research, and were not developed further.) It also outlines a number of criteria that should be met before clinical trials take place, and supports public funding for the research. The U.S. government does not allow federal funding for genetic research on embryos. The Oregon research was funded by the university.

"We don't want it to go speeding ahead," said Kelly Ormond, the lead author of the policy statement and a genetics professor at Stanford University in California. "We want people to be very transparent about what's happening and we want things to undergo good ethics review, and for society to actually be engaged in these dialogues now while this research is just starting to happen."

She said she believes it's important to be pro-active in talking and thinking about the issues related to the technology, and starting a broader conversation of how gene editing should and will be used.

"We can all agree that that world [of eugenics and designer babies] doesn't feel very comfortable, and I think most of us don't want to go there," she said. "So we need to find ways to prevent that from happening."